96. Crohn disease Clinical trials / Disease details
Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03172377 (ClinicalTrials.gov) | May 3, 2017 | 29/5/2017 | Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients | Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients | Crohn Disease in Remission;Crohn Disease | Other: Lengthening adalimumab dosing interval | Radboud University | Erasmus Medical Center | Active, not recruiting | 18 Years | N/A | All | 174 | Phase 4 | Netherlands |